- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
All News
Understanding Recent Developments in Mantle Cell Lymphoma
November 23, 2022
In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.
Intratumoral Injection Shows Antitumor Activity and Safety in Sarcoma
November 23, 2022
Investigators in the IT-01 trial of INT230-6 as monotherapy or combined with ipilimumab showed safety and potential efficacy in patients with sarcoma.
Verstovsek Highlights Future Directions for MPN Treatments
November 23, 2022
In an interview with Targeted Oncology, Srdan Verstovsek, MD, discussed the current MPN treatment landscape and where the field is shifting.
Targeting oxMIF Signals Promise as New Immuno-Oncology Option for mCRC
November 23, 2022
Preclinical data shows the potential of omFIX as a new immuno-oncology target which may be helpful in treating patients with metastatic colorectal cancers
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market
November 22, 2022
After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.
Updated Findings of Ponatinib/Blinatumomab Combo in Ph+ ALL are Encouraging
November 22, 2022
Fadi Haddad, MD, discusses the key points from the presentation he gave during the Tenth Annual Meeting of the Society of Hematologic Oncology.
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22, 2022
With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL
November 22, 2022
In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.
Pembrolizumab Combo Prolongs Survival in HER2–, Locally Advanced Unresectable or Metastatic Gastric/GEJ Cancers
November 22, 2022
Results from the phase 3 KEYNOTE-859 study show extended overall and progression-free survival in patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma treated with pembrolizumab and chemotherapy.
Molecular Testing to Treat and Diagnose Uterine Sarcoma
November 21, 2022
Matthew Ingham, MD, discusses understanding the genomics of sarcomas and how molecular testing can be useful in this space.